711 related articles for article (PubMed ID: 25686607)
1. Super-enhancers delineate disease-associated regulatory nodes in T cells.
Vahedi G; Kanno Y; Furumoto Y; Jiang K; Parker SC; Erdos MR; Davis SR; Roychoudhuri R; Restifo NP; Gadina M; Tang Z; Ruan Y; Collins FS; Sartorelli V; O'Shea JJ
Nature; 2015 Apr; 520(7548):558-62. PubMed ID: 25686607
[TBL] [Abstract][Full Text] [Related]
2. High-density P300 enhancers control cell state transitions.
Witte S; Bradley A; Enright AJ; Muljo SA
BMC Genomics; 2015 Nov; 16():903. PubMed ID: 26546038
[TBL] [Abstract][Full Text] [Related]
3. The Critical Role of Bach2 in Shaping the Balance between CD4
Yang L; Chen S; Zhao Q; Sun Y; Nie H
Mediators Inflamm; 2019; 2019():2609737. PubMed ID: 32082072
[TBL] [Abstract][Full Text] [Related]
4. A Bach2-Cebp Gene Regulatory Network for the Commitment of Multipotent Hematopoietic Progenitors.
Itoh-Nakadai A; Matsumoto M; Kato H; Sasaki J; Uehara Y; Sato Y; Ebina-Shibuya R; Morooka M; Funayama R; Nakayama K; Ochiai K; Muto A; Igarashi K
Cell Rep; 2017 Mar; 18(10):2401-2414. PubMed ID: 28273455
[TBL] [Abstract][Full Text] [Related]
5. Super-enhancers: Asset management in immune cell genomes.
Witte S; O'Shea JJ; Vahedi G
Trends Immunol; 2015 Sep; 36(9):519-26. PubMed ID: 26277449
[TBL] [Abstract][Full Text] [Related]
6. Enhancers and super-enhancers have an equivalent regulatory role in embryonic stem cells through regulation of single or multiple genes.
Moorthy SD; Davidson S; Shchuka VM; Singh G; Malek-Gilani N; Langroudi L; Martchenko A; So V; Macpherson NN; Mitchell JA
Genome Res; 2017 Feb; 27(2):246-258. PubMed ID: 27895109
[TBL] [Abstract][Full Text] [Related]
7. Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
Pelish HE; Liau BB; Nitulescu II; Tangpeerachaikul A; Poss ZC; Da Silva DH; Caruso BT; Arefolov A; Fadeyi O; Christie AL; Du K; Banka D; Schneider EV; Jestel A; Zou G; Si C; Ebmeier CC; Bronson RT; Krivtsov AV; Myers AG; Kohl NE; Kung AL; Armstrong SA; Lemieux ME; Taatjes DJ; Shair MD
Nature; 2015 Oct; 526(7572):273-276. PubMed ID: 26416749
[TBL] [Abstract][Full Text] [Related]
8. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Kubo S; Yamaoka K; Kondo M; Yamagata K; Zhao J; Iwata S; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2192-8. PubMed ID: 24013646
[TBL] [Abstract][Full Text] [Related]
9. Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice.
Adam RC; Yang H; Rockowitz S; Larsen SB; Nikolova M; Oristian DS; Polak L; Kadaja M; Asare A; Zheng D; Fuchs E
Nature; 2015 May; 521(7552):366-70. PubMed ID: 25799994
[TBL] [Abstract][Full Text] [Related]
10. Dissection and function of autoimmunity-associated TNFAIP3 (A20) gene enhancers in humanized mouse models.
Sokhi UK; Liber MP; Frye L; Park S; Kang K; Pannellini T; Zhao B; Norinsky R; Ivashkiv LB; Gong S
Nat Commun; 2018 Feb; 9(1):658. PubMed ID: 29440643
[TBL] [Abstract][Full Text] [Related]
11. Transcription factor co-occupied regions in the murine genome constitute T-helper-cell subtype-specific enhancers.
Fang Z; Hecklau K; Gross F; Bachmann I; Venzke M; Karl M; Schuchhardt J; Radbruch A; Herzel H; Baumgrass R
Eur J Immunol; 2015 Nov; 45(11):3150-7. PubMed ID: 26300430
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Hodge JA; Kawabata TT; Krishnaswami S; Clark JD; Telliez JB; Dowty ME; Menon S; Lamba M; Zwillich S
Clin Exp Rheumatol; 2016; 34(2):318-28. PubMed ID: 26966791
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional and epigenetic regulation of T-helper lineage specification.
Tripathi SK; Lahesmaa R
Immunol Rev; 2014 Sep; 261(1):62-83. PubMed ID: 25123277
[TBL] [Abstract][Full Text] [Related]
14. BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers.
Roychoudhuri R; Clever D; Li P; Wakabayashi Y; Quinn KM; Klebanoff CA; Ji Y; Sukumar M; Eil RL; Yu Z; Spolski R; Palmer DC; Pan JH; Patel SJ; Macallan DC; Fabozzi G; Shih HY; Kanno Y; Muto A; Zhu J; Gattinoni L; O'Shea JJ; Okkenhaug K; Igarashi K; Leonard WJ; Restifo NP
Nat Immunol; 2016 Jul; 17(7):851-860. PubMed ID: 27158840
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Tanaka Y; Maeshima K; Yamaoka K
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity.
Kanno Y; Vahedi G; Hirahara K; Singleton K; O'Shea JJ
Annu Rev Immunol; 2012; 30():707-31. PubMed ID: 22224760
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats.
Gertel S; Mahagna H; Karmon G; Watad A; Amital H
Clin Immunol; 2017 Nov; 184():77-81. PubMed ID: 28461107
[TBL] [Abstract][Full Text] [Related]
18. What are super-enhancers?
Pott S; Lieb JD
Nat Genet; 2015 Jan; 47(1):8-12. PubMed ID: 25547603
[TBL] [Abstract][Full Text] [Related]
19. CD8
He B; Xing S; Chen C; Gao P; Teng L; Shan Q; Gullicksrud JA; Martin MD; Yu S; Harty JT; Badovinac VP; Tan K; Xue HH
Immunity; 2016 Dec; 45(6):1341-1354. PubMed ID: 27986453
[TBL] [Abstract][Full Text] [Related]
20. STATs shape the active enhancer landscape of T cell populations.
Vahedi G; Takahashi H; Nakayamada S; Sun HW; Sartorelli V; Kanno Y; O'Shea JJ
Cell; 2012 Nov; 151(5):981-93. PubMed ID: 23178119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
